ArriVent BioPharma Inc 2024年度报告

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule405 of the Securities Act.Yes☒No☐ Indicate by check mark whether the registrant: (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Act of1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject tosuch filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the Registrant has submitted electronically; every Interactive Data File required to be submitted pursuant toRule405 of Regulation S-T (§232.0405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer⊠Smaller reporting company☒Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section404(b)of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm thatprepared or issued its auditreport.☐ If securities are registered pursuant to Section12(b)of the Act, indicate by check mark whether the financial statements of the registrant included inthe filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensationreceived by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒ The aggregate market value of the common stock held by non-affiliates of the registrant, based on the closing price of the shares of common stockon The Nasdaq Global Market on June 28, 2024 (the last business day of the registrant’s most recently completed second fiscal quarter), was$384,183,782. Documents Incorporated by ReferenceThe information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated herein by reference from the registrant’s definitive proxy statement relating to the Annual Meeting of Stockholders to be held in 2025, which definitive proxystatement shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Annual Reporton Form 10-K relates. TABLE OF CONTENTS PARTI Item1. Business5Item1A. Risk Factors60Item1B. Unresolved Staff Comments132Item 1C. Cybersecurity132Item2. Properties134Item3. Legal Proceedings135Item4. Mine Safety Disclosures135 PARTII Item5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchasesof EquitySecurities135Item6. [Reserved]137Item7. Management’s Discussion and Analysis of Financial Condition and Results of Operations137Item7A. Quantitative and Qualitative Disclosures About Market Risk146Item8. Financial Statements and Supplementary Data146Item9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure148Item9A. Controls and Procedures148Item9B. Other Information150Item9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections150PARTIIIItem10. Directors, Executive Officers and Corporate Governance150Item11. Executive Compensation150Item12. Security Ownership of Certain Beneficial Owners and Management and RelatedStockholder Matters150Item13. Certain Relationships and Related Transactions, and Director Independence151Item14. Principal Accountant Fees and Services151PARTIVItem15. Exhibits and Financial Statement Schedules151Item16. Form10-K Summary153Signatures154 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (Annual Report) contains forward-looking statements thatinvolve risks and uncertainties. All statements other than statements of historical facts contained in thisAnnual Report, including statements regarding our future results of operations and financial position,business strategy, plans for our product candidates, planned preclinical studies and clinical trials, resultsof clinical trials, future research and development co